Faricimab is a prescription medicine indicated for the treatment of patients with vABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Faricimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD). Diabetic Macular Edema (DME). Macular Edema Following Retinal Vein Occlusion (RVO)
Source: US FDA prescribing information
Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.
Source: US FDA prescribing information
For intravitreal injection. Neovascular (Wet) Age-Related Macular Degeneration (nAMD) The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44, 2) Weeks 24, 36 and 48, or 3) Weeks 20, 28, 36 and 44. Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.
Source: US FDA prescribing information
Ocular or periocular infection. Active intraocular inflammation. Hypersensitivity Ocular or Periocular Infections VABYSMO is contraindicated in patients with ocular or periocular infections.
Source: US FDA prescribing information
Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events (ATEs) associated with VEGF inhibition.
Source: US FDA prescribing information
The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity Endophthalmitis and retinal detachments Increase in intraocular pressure Thromboembolic events Retinal Vasculitis and/or Retinal Vascular Occlusion The most common adverse reactions (≥ 5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).
Source: US FDA prescribing information
Store VABYSMO in the refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. Prior to use, the unopened prefilled syringe or glass vial of VABYSMO may be kept at room temperature, 20°C to 25°C (68°F to 77°F), for up to 24 hours. Do not shake. Keep the sealed tray containing the prefilled syringe or the vial in the original carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Faricimab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Vabysmo 6 mg/0.05 mL injectionIntravitreal Cold chain | Genentech | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Faricimab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Faricimab, including Vabysmo.
Yes. The US FDA first approved Faricimab on 28 January 2022, according to Drugs@FDA.
Yes. Faricimab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Faricimab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Faricimab is classified under ATC code S01L (Eye medicines, subgroup S01L).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.